- $3.12bn
- $2.56bn
- $398.99m
- 64
- 21
- 41
- 36
Annual income statement for Zai Lab, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 49 | 144 | 215 | 267 | 399 |
| Cost of Revenue | |||||
| Gross Profit | 32.2 | 92.1 | 141 | 171 | 252 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 351 | 844 | 619 | 633 | 681 |
| Operating Profit | -302 | -700 | -404 | -367 | -282 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -268 | -703 | -443 | -335 | -257 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -268 | -703 | -443 | -335 | -257 |
| Equity in Affiliates | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -269 | -704 | -443 | -335 | -257 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -269 | -704 | -443 | -335 | -257 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.346 | -0.758 | -0.463 | -0.357 | -0.259 |